UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

Future oncology (London, England), 2019-03, Vol.15 (9), p.943-952

2019

Volltextzugriff (PDF)

ASSESSMENT OF RECENT OZONE SHORT-TERM EPIDEMIOLOGIC STUDIES

Inhalation toxicology, 2001, Vol.13 (1), p.1-24

2001

Volltextzugriff (PDF)

BERYLLIUM AND LUNG CANCER: A REANALYSIS OF A NIOSH COHORT MORTALITY STUDY

Inhalation toxicology, 2002-10, Vol.14 (10), p.1003-1015

2002

Volltextzugriff (PDF)

KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS4136-TPS4136

2018

Volltextzugriff (PDF)

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Antiviral research, 2013-09, Vol.99 (3), p.214-220

2013

Volltextzugriff (PDF)

Factor analysis of time series

Hwang, Peggy May Tan

1997

Volltextzugriff (PDF)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Clinical and molecular hepatology, 2019-12, Vol.25 (4), p.400

2019

Volltextzugriff (PDF)

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Clinical infectious diseases, 2014-12, Vol.59 (12), p.1657-1665

2014

Volltextzugriff (PDF)

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1075-1086

2015

Volltextzugriff (PDF)

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

The Journal of infection, 2023-11, Vol.87 (5), p.392-402

2023

Volltextzugriff (PDF)

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet (British edition), 2015-03, Vol.385 (9973), p.1087-1097

2015

Volltextzugriff (PDF)

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis

Virology (New York, N.Y.), 2013-09, Vol.443 (2), p.278-284

2013

Volltextzugriff (PDF)

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

Journal of clinical oncology, 2016-11, Vol.34 (33), p.4040-4046

2016

Volltextzugriff (PDF)

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ

Annals of Surgical Oncology, 2016-11, Vol.23 (12), p.3801-3810

2016

Volltextzugriff (PDF)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Clinical gastroenterology and hepatology, 2014-06, Vol.12 (6), p.1029-1037.e5

2014

Volltextzugriff (PDF)

Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease: A Retrospective Cohort Study

Drug safety, 2008-01, Vol.31 (4), p.325-334

2008

Volltextzugriff (PDF)

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

Journal of gastroenterology, 2018-05, Vol.53 (5), p.679-688

2018

Volltextzugriff (PDF)

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

Journal of the American Society of Hypertension, 2011-05, Vol.5 (3), p.166-176

2011

Volltextzugriff (PDF)

Corpus Callosum–Mediated Interhemispheric Interactions in Cervical Spondylotic Myelopathy

Journal of clinical neurophysiology, 2024-07, Vol.41 (5), p.473-477

2024

Volltextzugriff (PDF)

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre‐existing renal disease

Hepatology research, 2017-11, Vol.47 (12), p.1340-1345

2017

Volltextzugriff (PDF)

Utility of Sensory Nerve Conduction Study in Radiologically Positive Lumbosacral Plexopathy

Canadian journal of neurological sciences, 2024-01, Vol.51 (1), p.134-136

2024

Volltextzugriff (PDF)

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ

Practical Radiation Oncology, 2016-09, Vol.6 (5), p.287-295

2016

Volltextzugriff (PDF)

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Gastroenterology (New York, N.Y. 1943), 2017-05, Vol.152 (6), p.1372-1382.e2

2017

Volltextzugriff (PDF)

Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

Hepatology (Baltimore, Md.), 2017-02, Vol.65 (2), p.439-450

2017

Volltextzugriff (PDF)

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

Hepatology (Baltimore, Md.), 2017-09, Vol.66 (3), p.736-745

2017

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Humans
(32)
Female
(25)
Male
(22)
Middle Aged
(22)
Adult
(20)
Hepatitis C
(20)
Gastroenterology & Hepatology
(19)
Hepatitis
(18)
Aged
(16)
Hepacivirus - Genetics
(16)
Infections
(15)
Hepatitis C, Chronic - Drug Therapy
(14)
Genotype
(12)
Young Adult
(12)
Antiviral Agents - Therapeutic Use
(11)
Drug Therapy, Combination
(10)
Quinoxalines - Therapeutic Use
(10)
Treatment Outcome
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

ASSESSMENT OF RECENT OZONE SHORT-TERM EPIDEMIOLOGIC STUDIES

BERYLLIUM AND LUNG CANCER: A REANALYSIS OF A NIOSH COHORT MORTALITY STUDY

KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Factor analysis of time series

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis

Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease: A Retrospective Cohort Study

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

Corpus Callosum–Mediated Interhemispheric Interactions in Cervical Spondylotic Myelopathy

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre‐existing renal disease

Utility of Sensory Nerve Conduction Study in Radiologically Positive Lumbosacral Plexopathy

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

Suchergebnisse filtern